Topkan Erkan, Selek Ugur, Mertsoylu Hüseyin, Ozdemir Yurday, Kucuk Ahmet, Torun Nese, Besen Ali Ayberk
Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey.
Department of Radiation Oncology, Koc University School of Medicine, Istanbul, Turkey.
Clin Exp Otorhinolaryngol. 2020 Nov;13(4):407-414. doi: 10.21053/ceo.2019.01298. Epub 2020 Feb 21.
To investigate the influence of pretreatment primary tumor or nodal photopenia (PP) on 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT), an indicator of tumor ischemia, on survival results of nasopharyngeal cancers (NPCs) treated with concurrent chemoradiotherapy (C-CRT).
The pre-C-CRT FDG PET-CT scans of 104 patients with NPC (cT1-4 N0-3 M0) were retrospectively examined to determine the presence of PP (PP+). Our primary endpoint was the influence of PP+ on overall survival (OS), while the progression-free survival (PFS) and locoregional PFS (LRPFS) constituted the secondary endpoints.
The PP+ was detected in 29 (27.9%): nine (8.7%), seven (6.7%), and 13 (12.5%) in the primary tumor alone, primary tumor plus neck nodes, and neck nodes alone, respectively. Because the PP+ cases were small by count per location, all comparative analyses were performed according to overall PP+/ PP- status instead of per detected site. At a median follow-up of 67.8 months (range, 9 to 130 months), the median survival times were not reached (NR) for the entire population, while 5-year OS, LRPFS, and PFS rates were 73.3%, 68.2%, and 63.4%, respectively. Comparatively the PP+ patients exhibited significantly poorer median OS (49.8 months vs. NR, P<0.001), LRPFS (40.7 months vs. NR, P=0.001), and PFS (31.8 months vs. NR, P=0.002) durations than their PP- counterparts. Furthermore, the PP+ retained its independent prognostic significance in multivariate analysis (P<0.001).
Present results uncovered the pre-C-CRT PP as an independent predictor of poor prognosis for NPC patients, which underscore the requirement for the fortification of the local and systemic treatments in hypoxic NPCs.
探讨治疗前原发肿瘤或淋巴结放射性稀疏(PP),即肿瘤缺血的一个指标,对接受同步放化疗(C-CRT)的鼻咽癌(NPC)患者生存结果的影响。
回顾性分析104例NPC患者(cT1-4 N0-3 M0)在C-CRT前的18F-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(FDG PET-CT)图像,以确定是否存在PP(PP+)。我们的主要终点是PP+对总生存期(OS)的影响,而无进展生存期(PFS)和局部区域无进展生存期(LRPFS)为次要终点。
29例(27.9%)检测到PP+:仅原发肿瘤、原发肿瘤加颈部淋巴结、仅颈部淋巴结中分别有9例(8.7%)、7例(6.7%)和13例(12.5%)。由于每个部位PP+的病例数较少,所有比较分析均根据总体PP+/PP-状态而非检测部位进行。中位随访67.8个月(范围9至130个月),整个人群的中位生存期未达到(NR),而5年OS、LRPFS和PFS率分别为73.3%、68.2%和63.4%。相比之下,PP+患者的中位OS(49.8个月 vs. NR,P<0.001)、LRPFS(40.7个月 vs. NR,P=0.001)和PFS(31.8个月 vs. NR,P=0.002)持续时间明显短于PP-患者。此外,PP+在多变量分析中仍具有独立的预后意义(P<0.001)。
目前的结果表明,C-CRT前的PP是NPC患者预后不良的独立预测因素,这强调了对缺氧NPC患者加强局部和全身治疗的必要性。